BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9488127)

  • 1. Radiation following chemotherapy for mediastinal Hodgkin's disease: the outcome of various doses for bulky tumors.
    Eisbruch A; Kazerooni EA; Sahijdak WM; Francis IR; Lichter AS
    Radiother Oncol; 1998 Jan; 46(1):47-9. PubMed ID: 9488127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
    Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G;
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy.
    Elconin JH; Roberts KB; Rizzieri DA; Vermont C; Clough RW; Kim C; Dodge RK; Prosnitz LR
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1097-105. PubMed ID: 11072168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement.
    Lu NN; Li YX; Wu RY; Zhang XM; Wang WH; Jin J; Song YW; Fang H; Ren H; Wang SL; Liu YP; Liu XF; Chen B; Dai JR; Yu ZH
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):210-6. PubMed ID: 22436783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
    Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.
    Brice P; Bastion Y; Divine M; Nedellec G; Ferrant A; Gabarre J; Reman O; Lepage E; Fermé C
    Cancer; 1996 Sep; 78(6):1293-9. PubMed ID: 8826953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
    Bartlett NL; Rosenberg SA; Hoppe RT; Hancock SL; Horning SJ
    J Clin Oncol; 1995 May; 13(5):1080-8. PubMed ID: 7537796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M;
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients.
    Colonna P; Jais JP; Desablens B; Harousseau JL; Brière J; Boasson M; Lemevel A; Casassus P; Le Prisé PY; Guilhot F; Ghandour C; Lejeune F; Andrieu JM
    J Clin Oncol; 1996 Jun; 14(6):1928-35. PubMed ID: 8656262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.
    Hoppe BS; Flampouri S; Zaiden R; Slayton W; Sandler E; Ozdemir S; Dang NH; Lynch JW; Li Z; Morris CG; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1053-1059. PubMed ID: 24928256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The residual mediastinal mass following radiation therapy for Hodgkin's disease.
    Glenn LD; Kumar PP
    Am J Clin Oncol; 1991 Feb; 14(1):16-24. PubMed ID: 1987732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent mediastinal mass in a child with Hodgkin's disease following successful therapy: a diagnostic challenge.
    Feldges A; Wagner HP; Bubeck B; Kehrer B; Ries G; Schmid U; Waibel P
    Pediatr Surg Int; 1997; 12(8):613-7. PubMed ID: 9354739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of mediastinal mass in childhood Hodgkin's disease.
    Roskos RR; Evans RC; Gilchrist GS; Burgert EO; Ilstrup DM
    Cancer Treat Rep; 1982 Apr; 66(4):961-8. PubMed ID: 7074656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.
    Loeffler M; Diehl V; Pfreundschuh M; Rühl U; Hasenclever D; Nisters-Backes H; Sieber M; Tesch H; Franklin J; Geilen W; Bartels H; Cartoni C; Dölken G; Enzian J; Fuchs R; Gassmann W; Gerhartz H; Hagen-Aukamp U; Hiller E; Hinkelbein H; Hinterberger W; Kirchner H; Koch P; Krüger B; Schwarze EW
    J Clin Oncol; 1997 Jun; 15(6):2275-87. PubMed ID: 9196141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
    Brusamolino E; Lazzarino M; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Astori C; Livraghi A
    Ann Oncol; 1994; 5 Suppl 2():101-6. PubMed ID: 7515642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG).
    Eich HT; Gossmann A; Engert A; Kriz J; Bredenfeld H; Hansemann K; Skripnitchenko R; Brillant C; Pfistner B; Staar S; Diehl V; Müller RP;
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1187-92. PubMed ID: 17703895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.
    Chronowski GM; Wilder RB; Tucker SL; Ha CS; Younes A; Fayad L; Rodriguez MA; Hagemeister FB; Barista I; Cabanillas F; Cox JD
    Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):36-43. PubMed ID: 12504034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of mediastinal involvement in early stage Hodgkin's disease.
    Mauch P; Goodman R; Hellman S
    Cancer; 1978 Sep; 42(3):1039-45. PubMed ID: 698907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined modality (ABVD plus radiotherapy) versus radiotherapy in the management of early stage (IIA) Hodgkin's disease with mediastinal involvement.
    Anselmo AP; Bove M; Cartoni C; Damico C; Maurizi Enrici R; Falchetto Osti M; Biagini C
    Haematologica; 1992; 77(2):177-9. PubMed ID: 1383107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.